IP Library Granted Patent US 11,083,894
Granted Patent B2
US 11,083,894 · App. 16/359,218 · Granted Aug 10, 2021

Methods and apparatus to stimulate the heart

Inventors: Howard Levin (Teaneck, NJ); Mark Gelfand (New York, NY)
Assignee: BackBeat Medical, LLC
A61N1/36117A61N1/368A61N1/3621A61N1/3627A61N1/3684A61N1/36542A61N1/36564
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,083,894
App. No.
16/359,218
Granted
Aug 10, 2021
Kind
B2
Abstract

A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.

Claims (16)

1. A device for controlling heart contraction to reduce blood pressure, the device comprising:

at least one electrically conductive lead configured to connect to a heart of a patient;

an electrical pulse generator connectable to the at least one electrically conductive lead and configured to:

apply, after a first ventricular contraction of a ventricle of the heart, atrial pacing that causes an atrial contraction of an atrium of the heart that is not propagated to a second ventricular contraction,

monitor a heart rate of the patient resulting from the atrial pacing, and

apply backup pacing to the atrium and/or the ventricle when the heart rate is less than a predetermined minimum heart rate.

2. The device of claim 1 , wherein the electrical pulse generator is configured to apply the backup pacing to the atrium outside of an atrial refractory period of the atrium.

3. The device of claim 1 , wherein the electrical pulse generator is configured to continue to apply the backup pacing to maintain the heart rate above the predetermined minimum heart rate.

4. The device of claim 3 , wherein the predetermined minimum heart rate changes based on physical activity of the patient, and wherein the electrical pulse generator is configured to adjust the backup pacing to maintain the heart rate above a changed predetermined minimum heart rate.

5. The device of claim 1 , further comprising a sensor configured to sense ventricular depolarization of the heart, and wherein the electrical pulse generator is configured to apply the atrial pacing upon expiration of a predetermined delay from the sensed ventricular depolarization.

6. The device of claim 1 , wherein the electrical pulse generator is configured to apply the atrial pacing after an atrial refractory period.

7. The device of claim 1 , wherein the atrium of the heart has a normally-functioning valve.

8. The device of claim 1 , wherein the electrical pulse generator is configured to apply the atrial pacing such that the atrial contraction occurs against a closed atrioventricular valve and induces increased atrial wall stress resulting in ANP release by the stressed atrial wall.

9. The device of claim 1 , wherein the electrical pulse generator is configured apply the atrial pacing upon expiration of a predetermined delay following an atrial refractory period of the heart and during a ventricular refractory period of the heart.

10. The device of claim 1 , wherein the electrical pulse generator is configured to apply the atrial pacing while ventricular pressure is higher than atrial pressure and while AV conduction is refractory.

11. The device of claim 1 , wherein the electrical pulse generator is configured to apply the atrial pacing after an expiration of an atrial refractory period of the heart and during a ventricular refractory period of the heart, wherein the atrial contraction causes a vasodilation and ANP release in the heart.

Assignments (7)
SECURITY INTEREST Recorded Aug 7, 2025
From: ORCHESTRA BIOMED HOLDINGS, INC.; ORCHESTRA BIOMED, INC.; BACKBEAT MEDICAL, LLC; CALIBER THERAPEUTICS, LLC
To: MEDTRONIC, INC.
Reel/Frame 072341/0075 →
SECURITY INTEREST Recorded Aug 4, 2025
From: ORCHESTRA BIOMED HOLDINGS, INC.; ORCHESTRA BIOMED, INC.; BACKBEAT MEDICAL, LLC; CALIBER THERAPEUTICS, LLC
To: LIGAND PHARMACEUTICALS, INC.
Reel/Frame 072359/0219 →
SECURITY INTEREST Recorded Nov 6, 2024
From: ORCHESTRA BIOMED HOLDINGS, INC.; ORCHESTRA BIOMED, INC.; CALIBER THERAPEUTICS, LLC; BACKBEAT MEDICAL, LLC; FREEHOLD SURGICAL, LLC
To: HERCULES CAPITAL, INC.
Reel/Frame 069312/0758 →
SECURITY AGREEMENT Recorded Jun 6, 2022
From: ORCHESTRA BIOMED, INC.; CALIBER THERAPEUTICS, LLC; BACKBEAT MEDICAL, LLC; FREEHOLD SURGICAL, LLC; ACCELERATED TECHNOLOGIES, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 060286/0021 →
ENTITY CONVERSION Recorded Feb 13, 2020
From: BACKBEAT MEDICAL, INC.
To: BACKBEAT MEDICAL, LLC
Reel/Frame 051930/0075 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2019
From: G & L CONSULTING, LLC
To: BACKBEAT MEDICAL, INC.
Reel/Frame 049135/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2019
From: LEVIN, HOWARD; GELFAND, MARK
To: G & L CONSULTING, LLC
Reel/Frame 049150/0260 →
Cited By (1)
US 12,605,554